Conclusion: The most common pattern of diffuse large B-cell Non Hodgkin lymphoma
infiltration was bone marrow followed by interstitial tissue.
It included 50 cases of Hodgkin lymphoma
diagnosed on lymph node biopsy from August 2007 to August 2013.
Through our robust ongoing clinical investigation program, we have continued to see benefit of brentuximab vedotin, particularly in patients with Hodgkin lymphoma
or other CD30-positive malignancies who would typically face a poor prognosis.
There was no response to the treatment, excision biopsy was done and reported as Hodgkin Lymphoma
(Nodular Sclerosis type).
6) Additionally, RS-like cells in CLL/SLL cases are frequently positive for Epstein-Barr virus, which may play a role in the pathogenesis of these cells, as well as in the transformation to Hodgkin lymphoma
variant of Richter syndrome.
A snapshot of the global therapeutic scenario for Hodgkin Lymphoma
therapy with interleukin-4 receptor-directed cytotoxin in an infiltrating animal model.
7 December 2010 - Swiss-based pharma major Novartis AG (VTX: NOVN) said yesterday that its oral investigational drug LBH589 (panobinostat) demonstrated substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma
patients who had relapsed or had become refractory after an autologous stem cell transplant, in a Phase II clinical trial.
Nodular lymphocyte predominant Hodgkin lymphoma
has a male predominance and typically presents in middle age.
At the time of trial initiation, historical outcomes for Hodgkin lymphoma
patients who relapsed after an autologous stem cell transplant were poor, with median post-progression survival of 1.
INTRODUCTION: Hodgkin lymphoma
rarely occurs primarily as an extra nodal entity, especially in the head and neck region.
The pivotal, single-arm trial, which supported the FDA approval in 2011 of ADCETRIS for this indication, was conducted in 102 relapsed or refractory classical Hodgkin lymphoma
patients who had previously received an autologous stem cell transplant (ASCT) to assess the efficacy and safety of single-agent ADCETRIS.